

RESEARCH FEATURE SCHEDULE
Thursday, February 27 ♦ 4:25 p.m. – 5:05 p.m.
Exhibit Hall – Kierland Grand Ballroom 1 and 2

Screen A				
Times	Title	#	Presenter	Category
4:25 p.m. - 4:33 p.m.	De-Escalated Adjuvant Therapy after Transoral Robotic Surgery for HPV related Oropharyngeal Carcinoma: The SiRS Trial	100	Brett Miles	Definitive Management of Head and Neck Squamous Cell Carcinoma
4:33 p.m. - 4:41 p.m.	Risk Factors for Disease Progression Following Aggressive Dose De-Escalation for Adjuvant Chemoradiotherapy in Human Papillomavirus–Associated Oropharynx Squamous Cell Carcinoma (HPV-OSCC)	102	Daniel Ma	Definitive Management of Head and Neck Squamous Cell Carcinoma
4:41 p.m. - 4:49 p.m.	Semiquantitative analysis of tumor microenvironment from window of opportunity trial with nivolumab +/- Tadalafil in patients with Squamous Cell Carcinoma of the Head and Neck	104	Rohan Ganti	Definitive Management of Head and Neck Squamous Cell Carcinoma
4:49 p.m. - 4:57 p.m.	Circulating Hybrid Cells as a Marker of Nodal Metastases in Oral Cavity Squamous Cell Carcinoma	106	Yvette Anderson	Definitive Management of Head and Neck Squamous Cell Carcinoma
4:57 p.m. - 5:05 p.m.	Redefining Patients at Risk of Contralateral Neck Disease for HPV-positive Oropharyngeal Cancer: A Pathologic Study of Patients with Bilateral Neck Dissection	108	Andrew Smith	Definitive Management of Head and Neck Squamous Cell Carcinoma

Screen B				
Times	Title	#	Presenter	Category
4:25 p.m. - 4:33 p.m.	Low risk HPV associated oropharyngeal squamous cell carcinoma treated with induction chemoimmunotherapy followed by TORS or radiotherapy	101	Ari Rosenberg	Definitive Management of Head and Neck Squamous Cell Carcinoma
4:33 p.m. - 4:41 p.m.	Is Upfront Surgical Resection in HPV-Mediated Oropharyngeal Cancer Associated with Improved Outcomes?	103	Anna Torgeson	Definitive Management of Head and Neck Squamous Cell Carcinoma
4:41 p.m. - 4:49 p.m.	Survival Benefit of Postoperative Radiotherapy in Pathological N1 Oral Cavity Squamous Cell Carcinoma	105	Beth Beadle	Definitive Management of Head and Neck Squamous Cell Carcinoma
4:49 p.m. - 4:57 p.m.	nab-paclitaxel Monotherapy followed by Cetuximab and Radiation in Cisplatin-Unsuitable Patients with Locally Advanced Head and Neck Cancer: A Single-Arm, Multicenter Phase 2 Trial	107	Peter Oppelt	Definitive Management of Head and Neck Squamous Cell Carcinoma
4:57 p.m. - 5:05 p.m.	De-escalation with Definitive Unilateral Neck Radiation for T3 or N2b/N3 p16+ Tonsil Squamous Cell Carcinoma Using Prospectively Defined Criteria	109	Kenneth Hu	Definitive Management of Head and Neck Squamous Cell Carcinoma

CO-SPONSORS:



**MULTIDISCIPLINARY
HEAD and NECK CANCERS
SYMPOSIUM**



EXPANDING TREATMENT HORIZONS

The Westin Kierland Resort and Spa | Scottsdale, Arizona | February 27-29, 2020

Screen C				
Times	Title	#	Presenter	Category
4:25 p.m. - 4:33 p.m.	Examining the Prognostic Impact and Therapeutic Implications of Adjuvant Chemotherapy for Patients with Oral Cavity Squamous Cell Carcinoma and Extranodal Extension	110	Mohemmed Khan	Definitive Management of Head and Neck Squamous Cell Carcinoma
4:33 p.m. - 4:41 p.m.	Concurrent ChemoRadiation (CCR) is better than Accelerated Radiation Alone (ARA) in Patients with Moderate Advanced Head and Neck Squamous Cell Carcinoma (MAHNSCC). Mature results of HN08 Polish Trial	111	Dorota Książniak-Baran	Definitive Management of Head and Neck Squamous Cell Carcinoma
4:41 p.m. - 4:49 p.m.	The Role of Concomitant Chemoradiotherapy on Survival in AJCC 7 th Edition T1-2N1 Oropharyngeal Carcinoma in the HPV Era	112	Diana Lu	Definitive Management of Head and Neck Squamous Cell Carcinoma
4:49 p.m. - 4:57 p.m.	Profiling the Spatial Composition of the Hypoxic Tumor-Immune Microenvironment through Multiplex Immunohistochemistry in a Prospective cohort of HPV Associated Oropharynx Cancer	122	Linda Chen	Immunology and Immunotherapy
4:57 p.m. - 5:05 p.m.	Prognostic Significance of Cell Differentiation and Immune Pathway Mutations in Recurrent Laryngeal Squamous Cell Carcinoma	126	Molly Heft-Neal	Molecular Biology and Therapeutics

Screen D				
Times	Title	#	Presenter	Category
4:25 p.m. - 4:33 p.m.	Clinical Translation and Optimization of Dynamic Optical Contrast Imaging for Intraoperative Surgical Margin Assessment	113	Peter Pellionisz	Imaging, Physics, Pathology
4:33 p.m. - 4:41 p.m.	PET Imaging Biomarkers and Clinical Features to Predict Locoregional and Distant Failures in HPV-Associated Oropharyngeal Squamous Cell Carcinoma	114	Joel Wilkie	Imaging, Physics, Pathology
4:41 p.m. - 4:49 p.m.	The Role of SPECT-CT in Addition to PET for Lymphatic Drainage Mapping in Patients with HPV+ Oropharyngeal Squamous Cell Carcinoma	115	Andrew Rosko	Imaging, Physics, Pathology
4:49 p.m. - 4:57 p.m.	HPV/p16 status of cervical lymph node metastases in oropharyngeal squamous cell carcinoma by molecular testing of FNA samples	116	Christian Pingree	Imaging, Physics, Pathology
4:57 p.m. - 5:05 p.m.	Systematic Review and Meta-analysis of Quality of Life Outcomes Based on Type of Treatment for HPV-associated Oropharyngeal Cancer	129	Daniel Quan	Toxicity, Quality of Life, Survivorship, Costs of Care

CO-SPONSORS:



**MULTIDISCIPLINARY
HEAD and NECK CANCERS
SYMPOSIUM**



EXPANDING TREATMENT HORIZONS

The Westin Kierland Resort and Spa | Scottsdale, Arizona | February 27-29, 2020

Screen E

Times	Title	#	Presenter	Category
4:25 p.m. - 4:33 p.m.	Exceptional Responders to Immunotherapy in Head and Neck Cancer	117	Mercedes Porosnicu	Immunology and Immunotherapy
4:33 p.m. - 4:41 p.m.	Predictors of Immunotherapy Response in Head and Neck Cancer: Per Lesion Analysis of a Prospective Randomized Trial with Nivolumab	118	Yao Yu	Immunology and Immunotherapy
4:41 p.m. - 4:49 p.m.	Health-Related Quality of Life of Pembrolizumab for Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma in KEYNOTE-629	119	Jessica Bauman	Immunology and Immunotherapy
4:49 p.m. - 4:57 p.m.	CD26 in checkpoint blockade-induced tumor immunity	120	Hannah Knochelmann	Immunology and Immunotherapy
4:57 p.m. - 5:05 p.m.	A Multidimensional Gene Expression Model that Accurately Predicts Tumor Response to Pembrolizumab or Nivolumab	121	Douglas Adkins	Immunology and Immunotherapy

Screen F

Times	Title	#	Presenter	Category
4:25 p.m. - 4:33 p.m.	Viable Circulating Ensembles of Tumor Associated Cells Persist in Patients with No Radiologically Detectable Disease After Treatment in Head and Neck Cancer	123	Ajay Srinivasan	Management of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
4:33 p.m. - 4:41 p.m.	Encyclopedic Tumor Analysis Guided Treatments with Conventional Drugs Outperform Available Alternatives in Refractory Head and Neck Cancers.	124	Dadasheb Akolkar	Management of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
4:41 p.m. - 4:49 p.m.	Sentinel Node Status to Guide Adjuvant Radiation Therapy in Patients with Merkel Cell Carcinoma	127	Tessnim Ahmad	Non-squamous Cell Malignancies: thyroid, sarcomas, skin cancers, salivary gland and sinus cancers
4:49 p.m. - 4:57 p.m.	Immune Status and the Efficacy of Adjuvant Radiotherapy for Patients with Localized Merkel Cell Carcinoma of the Head and Neck	128	Michael May	Non-squamous Cell Malignancies: thyroid, sarcomas, skin cancers, salivary gland and sinus cancers
4:57 p.m. - 5:05 p.m.	HNSCC-associated CASP8 mutations promote resistance to apoptosis and mediate induction of immunosuppressive cytokines	LBA 3	Zhibin Cui	Molecular Biology and Therapeutics

CO-SPONSORS:

